

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

BK



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C07D 411/04, 239/00 // C07H 19/06</b>	<b>A1</b>	(11) International Publication Number: <b>WO 96/30369</b> (43) International Publication Date: 3 October 1996 (03.10.96)
(21) International Application Number: <b>PCT/EP96/01353</b> (22) International Filing Date: <b>26 March 1996 (26.03.96)</b> (30) Priority Data: <b>9506644.5</b> <b>31 March 1995 (31.03.95)</b> <b>GB</b> (71) Applicant (for all designated States except US): <b>THE WELL-COME FOUNDATION LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).</b> (72) Inventors; and (75) Inventors/Applicants (for US only): <b>SAMANO, Mima, C. [MX/US]; Glaxo Wellcome Inc., Five Moore Drive, Box 13398, Research Triangle Park, NC 27709 (US). SAMANO, Vicente [MX/US]; Glaxo Wellcome Inc., Five Moore Drive, Box 13398, Research Triangle Park, NC 27709 (US). GOODYEAR, Michael, David [GB/GB]; Glaxo Research and Development Limited, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB).</b> (74) Agent: <b>QUILLIN, Helen, K.; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).</b>		(81) Designated States: <b>AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</b>  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

(54) Title: **PROCESS FOR THE SYNTHESIS OF NUCLEOSIDE ANALOGUES**

## (57) Abstract

The present invention is concerned with a process for the preparation of antiviral 1,3-oxathiolane nucleosides comprising an intramolecular glycosylation reaction to produce exclusively the  $\beta$ -diastereomer, and intermediates useful in the process.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

## **PROCESS FOR THE SYNTHESIS OF NUCLEOSIDE ANALOGUES**

The present invention is concerned with a process for the preparation of anti-viral 1,3-oxathiolane nucleosides, which employs an intramolecular glycosylation to produce exclusively the  $\beta$ -diastereomer. The invention also relates to novel intermediates obtained by the process.

1,3-Oxathiolane nucleosides possess two chiral centres (at the C1'- and C4'-positions according to the furanose numbering system) and typically exist as diastereomeric pairs of the  $\alpha$ - and  $\beta$ -forms, each form comprising two enantiomers. The  $\alpha$ - and  $\beta$ -diastereoisomers tend to have different anti-viral activities, the  $\beta$ -form typically being the more potent. Similarly, the enantiomeric pairs of each diastereomer tend to have different properties.

$\beta$ -Diastereomers have traditionally been obtained by preparation of the diastereomeric mixture followed by laborious separation of the  $\beta$ -form by physical means such as differential solubility or chromatography. It follows that the overall yield of  $\beta$ -isomer is typically less than 50%.


International Patent Application No. WO91/11186 describes a process whereby 1,3-oxathiolane nucleosides may be obtained with high  $\beta$ -diastereoselectivity by condensing a carbohydrate or carbohydrate-like moiety with a heterocyclic base in the presence of a specific Lewis acid, typically stannic chloride. The process is further exemplified in International Patent Application No. WO92/14743.

Further diastereoselective processes for the preparation of nucleoside analogues involving condensation of a carbohydrate or like moiety with a purine or pyrimidine base are described in WO92/20669 and WO95/29174.


We have now developed an efficient new process which provides exclusively the  $\beta$ -diastereomer of a 1,3-oxathiolane pyrimidine nucleoside with no  $\alpha$ -contamination. The critical steps involved in the synthesis are cyclisation of an appropriate heterocyclic acetaldehyde with 1,4-dithiane-2,5-diol to give a "5'-tethered" 1,3-oxathiolane nucleoside analogue which then undergoes an

intramolecular glycosylation on the same face of the carbohydrate ring to give exclusively the (1'-tethered)  $\beta$ -diastereomer. The intramolecular glycosylation of 5'-tethered furanose nucleosides is known from, *inter alia*, Japanese Patent No. 06263792-A, but the prior art comprises no reports of applying such methodology to the preparation of anti-viral 1,3-oxathiolane nucleosides. The resulting  $\beta$ -diastereomer may be hydrolysed to the corresponding cytidine analogue or may be resolved by any suitable technique known to a skilled person, for example, by esterification followed by selective enzymatic hydrolysis, removal of the 'unwanted' enantiomer and hydrolysis of the ester of desired enantiomeric configuration. Alternatively, it may be possible, for example, by use of a chiral auxiliary, to obtain intermediates substantially enantiomerically pure which intermediates can be carried forward to yield the desired enantiomerically pure product.

According to one aspect of the present invention, there is provided a process for the preparation of compounds of formula (I)



wherein R is hydrogen, C<sub>1-6</sub> alkyl, or halogen and Y is hydroxy, amino, C<sub>1-6</sub> alkoxy or OR<sup>1</sup>, where R<sup>1</sup> is a chiral auxiliary, which process comprises treating a compound of formula (II)



wherein R and Y are as hereinbefore defined and  $R^2$  represents hydrogen,  $C_{1-6}$ acyl,  $C_{1-6}$ alkyl or halogen with a suitable Lewis acid or a reagent apt to convert the group  $OR^2$  to a leaving group.

Suitable Lewis acids include, for example, stannic chloride or trimethylsilyl triflate. Reaction with a Lewis acid is suitably conducted at reduced temperature (e.g.  $0^{\circ}C$  to  $-20^{\circ}C$ ) in a polar aprotic solvent followed by treatment with base.

Where  $R^2$  is H, the group  $OR^2$  may conveniently be converted to a leaving group by reaction with a halogenating agent such as a thionyl halide or an oxalyl halide, or a tosyl or mesyl halide. Other methods for converting  $OR^2$  to a leaving group (i.e. a group which can be readily displaced by the ring nitrogen atom) will be apparent to those skilled in the art.

It is to be understood that where the variable R occurs more than once in a general formula, it may represent the same group at each position, or different groups.


As used herein halogen means bromine, chlorine, fluorine or iodine, especially chlorine or fluorine, more especially fluorine.

The term "chiral auxiliary" describes an asymmetric molecule that is used to effect the chemical resolution of a racemic mixture. Such chiral auxiliaries may possess one chiral centre such as  $\alpha$ -methylbenzylamine or several chiral centres such as menthol. The purpose of the chiral auxiliary, once built into the starting material, is to allow simple separation of the resulting diastereomeric mixture. See, for example, J Jacques et al., Enantiomers, Racemates and Resolutions, pp. 251-369, John Wiley & Sons, New York (1981).


Where  $R^1$  represents a chiral auxiliary it will preferably be selected from (d)-menthyl, (l)-menthyl, (d)-8-phenylmenthyl, (l)-8-phenylmenthyl, (+)-

norephedrine and (-)-norephedrine. More preferably  $R^1$  is (l)-menthyl, or (d)-menthyl, most preferably (l)-menthyl.

According to a further aspect, the present invention provides a process for the preparation of a compound of formula (Ia)




wherein R and Y are as previously defined, which process comprises treating a compound of formula (IIa)



wherein R, Y and R<sup>2</sup> are as previously defined with a suitable Lewis acid or a reagent apt to convert the group OR<sup>2</sup> to a leaving group.

According to another aspect of the invention, there is provided a process for the preparation of compounds of formula (II) which comprises reacting a compound of formula (III)



wherein R and Y are as hereinbefore defined, with 1,4-dithiane-2,5-diol at elevated temperature (e.g. 100°C) in a non-polar aprotic solvent to give a compound of formula (II) wherein  $R^2$  is H. Compounds of formula (II) wherein  $R^2$  is other than H may be prepared from the corresponding hydroxy compound by derivatisation using any standard procedure, for example, treatment with alkanoyl halide/base or carboxylic anhydride/base.

Reaction of a compound of formula (III) with 1,4-dithiane-2,5-diol results in a mixture of isomers of the compounds of formula (II) wherein  $R^2$  is H. Where Y is  $OR^1$ , the compounds of formula (IIa) may be selectively crystallized from the diastereomeric mixture. In a further or alternative aspect, the present invention accordingly provides a method for obtaining the compound of formula (IIa) wherein R is H and Y is  $OR^1$  from a mixture of isomers by treatment of the mixture of isomers, at least partially in solution, with an agent capable of effecting interconversion of the isomers without complete suppression of the crystallisation of the desired single enantiomer (IIa) wherein R is H and Y is  $OR^1$ . Other compounds of formula (IIa) may be prepared from compounds of formula (IIa) wherein R is H and Y is  $OR^1$  by conventional methods.

Agents capable of effecting interconversion of the isomers without complete suppression of the crystallisation of the trans isomers include, for example, alcohols, such as, for example, methanol, ethanol, n-propanol, i-propanol, n-butanol, i-butanol, t-butanol, and organic bases, in particular tertiary amines, for example, pyridine and triethylamine and Hunig's base. A preferred agent is triethylamine.

The interconversion of isomers may be effected in any suitable solvent or mixture of solvents which does not otherwise react with the alcohols of formula (II), under conditions of concentration and temperature which permit crystallisation of the desired isomer or isomers and which do not cause significant degradation of the desired isomer or isomers. Suitable solvents may include for example, aliphatic or aromatic hydrocarbons, ethers, esters and chlorinated hydrocarbons. The interconversion will preferably be effected



at a temperature of about  $-20^{\circ}$  to  $120^{\circ}\text{C}$ , more preferably in the range of about  $-10^{\circ}$  to  $80^{\circ}\text{C}$ , such as about  $0^{\circ}$  to  $50^{\circ}\text{C}$ .


It will be appreciated by those skilled in the art that selection of solvent, temperature, interconversion agent and, particularly, the quantity of the interconversion agent is best conducted as an integrated exercise dependent on the nature of the groups R, R<sup>1</sup> and R<sup>2</sup> present in the isomers. However, when an organic base is used as the interconversion agent, the preferred quantity is generally less than two mole-equivalents based on the total of all isomers of (II) present.

The interconversion of isomers may be conducted separately from the preparation of the isomeric mixture; however, it is conveniently conducted concomitantly with that preparation.

The interconversion procedure may also be used to increase the isomeric purity of isolated (IIa).


By means of the interconversion process, the isolated yield of the desired isomer (IIa) may be enhanced to greater than 50% of theory (based on formation of all stereoisomers), typically to between about 60% and about 90% of theory; but it is not ruled out that yields approaching 100% of theory may be obtained.

Compounds of formula (III) may be prepared by reacting a compound of formula (IV)




wherein R (which may be the same or different) and Y are as hereinbefore defined, with aqueous trifluoroacetic acid (90%) at elevated temperature.

Compounds of formula (IV) may be prepared by reacting a compound of formula (V)




wherein R and Y are as hereinbefore defined and Z is a suitable leaving group, for example, chlorine, with a compound of formula (VI)



wherein R (which may be the same or different) are as hereinbefore defined, at reduced temperature in a polar aprotic solvent in the presence of base.

Compounds of formula (V) may be prepared by reacting a compound of formula (VII)




wherein R and Z (which may be the same or different) are as hereinbefore defined, with a suitable nucleophile, for example, in the case where Y in the compound of formula (V) is to be ethoxy, EtO<sup>-</sup> (NaOEt/EtOH).

Compounds of formulae (VI) and (VII) may be obtained commercially or prepared from commercially available starting materials by methods known to a skilled person, for example, in the case where R in the compound of

formula (VII) is to be fluorine and Z chlorine, by treating 5-fluorouracil with phosphorus oxychloride at elevated temperature in the presence of base.

As indicated, compounds of formula (I) wherein Y at the C4-position is C<sub>1-6</sub> alkoxy or OR<sup>1</sup> may be converted to a cytidine analogue (Y=NH<sub>2</sub>) by heating with ammoniacal methanol or, where racemic, may be resolved by any suitable technique known to a skilled person, for example, by one of the enzyme procedures described in International Patent No. WO92/14743.

According to such a procedure, the racemic  $\beta$ -diastereomer (I) is esterified at the C5'-position using, for example, butyric anhydride, and the racemic ester (VIII) is treated with a suitable enzyme, typically pig liver esterase, to preferentially hydrolyse the 'unwanted' enantiomer back to the 5'-OH compound (IX) which is water-soluble and can be separated from the desired (unhydrolysed) enantiomer (X). The latter is converted to the 4-NH<sub>2</sub>, 5'-OH compound of desired enantiomeric configuration by heating with ammoniacal methanol.



The process of the invention finds particular application in the preparation of (2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine, (2R,5S)-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine, (±)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-cytosine and (±)-cis-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine.

According to a further aspect of the invention, there are provided novel compounds of formulae (IV), (III), (II) and (I) (which latter includes the

racemate, the (2S,5R)-enantiomer (IX), the esterified racemate (VIII) and the esterified (2R,5S)-enantiomer (X)). Specific intermediate compounds arising from the preparation of (2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine, (2R,5S)-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine, (±)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-cytosine and (±)-cis-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine include:

2-(2,2-Dimethoxyethoxy)-4-ethoxy-5-fluoropyrimidine  
2-(2,2-Dimethoxyethoxy)-4-ethoxypyrimidine  
2-[(4-Ethoxy-5-fluoro-2-pyrimidinyl)oxy]acetaldehyde  
2-[(4-Ethoxy-2-pyrimidinyl)oxy]acetaldehyde  
2-[[[(4-Ethoxy-5-fluoro-2-pyrimidinyl)oxy]methyl]-1,3-oxathiolan-5-ol  
2-[[[(4-Ethoxy-2-pyrimidinyl)oxy]methyl]-1,3-oxathiolan-5-ol  
2-[[[(4-Ethoxy-5-fluoro-2-pyrimidinyl)oxy]methyl]-1,3-oxathiolan-5-yl acetate  
2-[[[(4-Ethoxy-2-pyrimidinyl)oxy]methyl]-1,3-oxathiolan-5-yl acetate  
(2S\*, 5R\*)-4-Ethoxy-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one  
(2S\*, 5R\*)-4-Ethoxy-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one  
(2S\*, 5R\*)-4-Ethoxy-5-fluoro-1-[2-(propionyloxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one  
(2S\*, 5R\*)-4-Ethoxy-1-[2-(propionyloxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one  
(2S, 5R)-4-Ethoxy-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one  
(2S, 5R)-4-Ethoxy-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one  
(2R, 5S)-4-Ethoxy-5-fluoro-1-[2-(propionyloxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one  
(2R, 5S)-4-Ethoxy-1-[2-(propionyloxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one

The following examples of the process of the invention are for illustration only and are not intended to limit the scope of the invention in any way. In all cases, <sup>1</sup>H NMR and C,H,N elemental analysis were consistent with the proposed structure.

Example 1Preparation of (2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine(a) 2,4-Dichloro-5-fluoropyrimidine

To a suspension of 5-fluorouracil (Aldrich, 8.00 g, 61.5 mmol) in phosphorus oxychloride (25.0 mL, 41.12 g, 268 mmol) was added N,N-diethylaniline (12.6 mL, 11.81 g, 80 mmol) and the mixture was heated at 100°C for 1.5 hours. Solvent was evaporated *in vacuo* and the residue poured into cold H<sub>2</sub>O/Et<sub>2</sub>O (400 mL, 1:1). The aqueous phase was extracted with Et<sub>2</sub>O and the combined organic phase was dried (Na<sub>2</sub>SO<sub>4</sub>) and evaporated (water aspirator pump, 35°C) to give the desired product (10.2 g, 99%) as a yellowish solid: mp 34-36°C (lit. 35-36°C).

(b) 2-Chloro-4-ethoxy-5-fluoropyrimidine

To a solution of the product from step (a) (10.0 g, 59.9 mmol) in abs. EtOH (40 mL) at 0°C under nitrogen atmosphere was added 1M NaOEt/EtOH (61 mL, 61 mmol) and the mixture was stirred for 1 hour. Solvent was evaporated *in vacuo* and the residue partitioned between H<sub>2</sub>O and Et<sub>2</sub>O. The aqueous phase was extracted with Et<sub>2</sub>O and the combined organic phase was washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>) and evaporated (water aspirator pump, 35°C) to provide the desired product (8.74 g, 83%) as a yellowish solid: mp 30-32°C (lit. 31-32°C); <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.46 (t, J = 7.0 Hz, 3H), 4.53 (quartet, J = 7 Hz, 2H), 8.17 (d, J = 2.1 Hz, 1H); MS *m/z* 179 (M + 3, 17%), 177 (M + 1, 50%), 149 (100%). Anal. Calcd. for C<sub>6</sub>H<sub>6</sub>ClFN<sub>2</sub>O: C, 40.81; H, 3.42; N, 15.86. Found, C, 40.90; H, 3.45; N, 15.81.

(c) 2-(2,2-Dimethoxyethoxy)-4-ethoxy-5-fluoropyrimidine

To a suspension of 60% NaH/mineral oil (2.88 g, 72.2 mmol) in anhydrous DMF (70 mL) at 0°C under nitrogen atmosphere was slowly added glycolaldehyde dimethyl acetal (Lancaster, 6.13 g, 57.7 mmol). The mixture was stirred at ambient temperature for 1 hour and then transferred to a solution of the product from step (b) (8.5 g, 48.1 mmol) in anhydrous DMF (70 mL) at -55°C over 15 minutes. The mixture was allowed to warm to -20°C over 2 hours and then neutralized with AcOH. Solvent was evaporated *in vacuo* and the residue partitioned between H<sub>2</sub>O and CH<sub>2</sub>Cl<sub>2</sub>. The aqueous phase was extracted with CH<sub>2</sub>Cl<sub>2</sub> and the combined organic phase was dried (Na<sub>2</sub>SO<sub>4</sub>) and evaporated. The residue was flash chromatographed (EtOAc/hexanes, 1:5) to give the desired product (9.75 g, 82%) as an oil: <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.42 (t, J = 7.0 Hz, 3H), 3.43 (s, 6H), 4.32 (d, J = 5.2 Hz, 2H), 4.50 (quartet, J = 7.0 Hz, 2H), 4.75 (t, J = 5.2 Hz, 1H), 8.03 (d, J = 2.4 Hz, 1H); MS *m/z* 215 (M - OCH<sub>3</sub>, 100%). Anal. Calcd. for C<sub>10</sub>H<sub>15</sub>FN<sub>2</sub>O<sub>4</sub>: C, 48.78; H, 6.14; N, 11.38. Found: C, 48.84; H, 6.06; N, 11.36.

(d) 2-[(4-Ethoxy-5-fluoro-2-pyrimidinyl)oxy]acetaldehyde

A mixture of the product from step (c) (6.0 g, 24.4 mmol) and 90% TFA/H<sub>2</sub>O (50 ml) was heated at 50°C for 2.5 hours. Solvent was evaporated *in vacuo* and the residue partitioned between CHCl<sub>3</sub> and saturated NaHCO<sub>3</sub>/H<sub>2</sub>O. The aqueous phase was extracted with CHCl<sub>3</sub> (x2) and the combined extracts dried (Na<sub>2</sub>SO<sub>4</sub>) and evaporated to give the desired product (4.82 g, 99%) as a colourless oil which was used in the next step without further purification. Flash chromatography (EtOAc/hexanes, 1:2) gave analytically pure material as a colourless oil: <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.43 (t, J = 7.0 Hz, 3H), 4.40 (quartet, J = 7.0 Hz, 2H), 4.81 (s, 2H), 8.03 (d, J = 1.8 Hz, 1H), 9.74 (s, 1H); MS *m/z* 201 (M + 1, 100%). Anal. Calcd. for C<sub>8</sub>H<sub>9</sub>FN<sub>2</sub>O<sub>3</sub>·0.25 H<sub>2</sub>O: C, 46.95; H, 4.68; N, 13.69. Found: C, 46.81; H, 4.61; N, 13.64.

(e) 2-[[[4-Ethoxy-5-fluoro-2-pyrimidinyl)oxy)methyl]-1,3-oxathiolan-5-ol

A mixture of the product from step (d) (4.6 g, 23.0 mmol) and 1,4-dithiane-2,5-diol (Aldrich, 1.92 g, 12.65 mmol) in anhydrous toluene (90 mL) was heated at 100°C for 2 hours. The mixture was filtered and the filtrate was concentrated and dried *in vacuo* to give the desired product (6.27 g, 99%) as a waxy pale yellow solid which was used in the next step without further purification (~1:1 diastereomeric ratio by <sup>1</sup>H NMR spectroscopy). Flash chromatography (EtOAc/hexanes, 1:2) afforded analytically pure material as a white solid: mp 85-87°C; <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.41 (t, J = 7.0 Hz, 3H), 2.42 (br s, 1H), 3.10 (d, J = 11.0 Hz, 1H), 3.20 (dd, J = 11.0, 3.5 Hz, 1H), 4.40 (dd, J = 12.0, 3.5 Hz, 1H), 4.43 (quartet, J = 7.0 Hz, 2H), 4.77 (dd, J = 12.0, 7.0 Hz, 1H), 5.70 (dd, J = 7.0, 3.5 Hz, 2H), 5.92 (d, J = 3.5 Hz, 1H), 8.04 (d, J = 2.5 Hz, 1H); a similar set of signals appeared for the other diastereomer; MS *m/z* 201 (M - C<sub>2</sub>H<sub>3</sub>OS, 100%). Anal. Calcd. for C<sub>10</sub>H<sub>13</sub>FN<sub>2</sub>O<sub>4</sub>S: C, 43.47; H, 4.74; N, 10.14; S, 11.61. Found: C, 43.56; H, 4.78; N, 10.04; 11.66.

(f) 2-[[[4-Ethoxy-5-fluoro-2-pyrimidinyl)oxy]methyl]-1,3-oxathiolan-5-yl acetate

To a solution of the product from step (e) (1.0 g, 3.62 mmol) and pyridine (0.8 mL, 0.78 g, 9.88 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (12 mL) at 0°C was added AcCl (0.35 mL, 0.37 g, 4.7 mmol). After 1 hour at ambient temperature, saturated NaHCO<sub>3</sub>/H<sub>2</sub>O was added and the aqueous phase was extracted with CHCl<sub>3</sub>. The combined organic phase was washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), evaporated and dried *in vacuo* to give the desired product (1.13 g, 99%) as a yellow oil which was used in the next step without further purification (~2:1 diastereomeric ratio by <sup>1</sup>H NMR spectroscopy). Flash chromatography (acetone/CH<sub>2</sub>Cl<sub>2</sub>, 1:24) gave analytically pure material as a colourless oil: <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.42 (t, J = 7.0 Hz, 3H), 2.07 (s, 3H), 3.15 (d, J = 11.5 Hz, 1H), 3.38 (dd, J = 11.5, 4.0 Hz, 1H), 4.40-4.60 (m, 4H), 5.73 (m, 1H), 6.70 (d, J = 4.0 Hz, 1H), 8.03 (d, J = 2.5 Hz, 1H); a similar set of signals appeared for the minor diastereomer; MS *m/z* 259 (M - OAc,

9%), 159 (100%). Anal. Calcd. for  $C_{12}H_{15}FN_2O_5S$ : C, 45.28; H, 4.75; N, 8.80; S, 10.07. Found: C, 45.35; H, 4.76; N, 8.83; S, 10.11.

(g) (2S\*,5R\*)-4-Ethoxy-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one

To a mixture of the product from step (f) (0.21 g, 0.66 mmol) and 4Å molecular sieves (0.3 g) in anhydrous  $CH_3CN$  (20 mL) at  $-20^{\circ}C$  under nitrogen atmosphere was slowly added trimethylsilyl triflate (Aldrich, 0.14 mL, 0.16 g, 0.73 mmol). After stirring the mixture for 2 hours at  $-20^{\circ}C$ , 1M NaOH/ $H_2O$  (2.0 mL, 2.0 mmol) was added. After 2 hours at  $0^{\circ}C$ , the mixture was neutralized with AcOH. Solvent was evaporated *in vacuo* and the residue flash chromatographed (EtOAc/hexanes, 9:1) to give the desired product (0.11 g, 60%) as a white solid: mp  $162-164^{\circ}C$ ;  $^1H$  NMR ( $DMSO-d_6$ ):  $\delta$  1.39 (t,  $J = 7.0$  Hz, 3H), 3.29 (dd,  $J = 12.0, 2.7$  Hz, 1H), 3.60 (dd,  $J = 12.0, 5.4$  Hz, 1H), 3.82 (ddd,  $J = 12.5, 5.4, 3.5$  Hz, 1H), 3.95 (ddd,  $J = 12.5, 5.4, 3.5$  Hz, 1H), 4.45 (quartet,  $J = 7.0$  Hz, 2H), 5.31 (t,  $J = 3.5$  Hz, 1H), 5.63 (t,  $J = 5.4$  Hz, 1H), 6.20 (m, 1H), 8.74 (d,  $J = 6.7$  Hz, 1H); MS  $m/z$  277 ( $M + 1$ , 4%), 159 (100%). Anal. Calcd. for  $C_{10}H_{13}FN_2O_4S$ : C, 43.47; H, 4.74; N, 10.14; S, 11.61. Found: C, 43.54; H, 4.76; N, 10.18; S, 11.52.

(h) (2S\*,5R\*)-4-Ethoxy-5-fluoro-1-[2-(propionyloxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one

To a solution of the product from step (g) (90 mg) in pyridine (0.2 mL) was added butyric anhydride (1.0 mL) and the resulting mixture was stirred at ambient temperature for 18 hours. Ice-water was added and the aqueous solution was adjusted to pH 2 with 1N HCl/ $H_2O$  and extracted with  $CHCl_3$  (x3). The combined organic phase was washed with saturated  $NaHCO_3$ / $H_2O$  and brine, dried ( $Na_2SO_4$ ) and concentrated *in vacuo*. The resulting oil was dried *in vacuo* at  $50^{\circ}C$  for 18 hours under a stream of nitrogen to obtain the desired product (100 mg) as a colourless solid:  $^1H$  NMR ( $CDCl_3$ ):  $\delta$  0.99 (t, 3H), 1.42 (t,



3H), 1.70 (sextuplet, 2H), 2.42 (t, 2H), 3.23 (d, 1H), 3.60 (dd, 1H), 4.45 (dd, 1H), 4.50 (quartet, 2H), 4.65 (dd, 1H), 5.40 (m, 1H), 6.30 (m, 1H), 8.15 (d, 1H); MS  $m/z$  347 ( $M + 1$ , 25%), 159 (100%).

(i) (2R,5S)-4-Ethoxy-5-fluoro-1-[2-(propionyloxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one

To a solution of the product from step (h) (10 mg) in 20% CH<sub>3</sub>CN/buffer (3.0 mL, 0.05 M, pH 8.0, phosphate) was added PLE (pig liver esterase, 1.5  $\mu$ L, Sigma) and the mixture was stirred at ambient temperature for 24 hours. The aqueous solution was extracted with hexane (x2) and the combined extracts were dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated *in vacuo*. HPLC analysis (Chiral Pack AS; EtOH; 1.5 ml/min) of the organic extracts indicated the presence of a single enantiomeric butyrate ester (4 mg). The enantiomeric alcohol was detected in the aqueous phase. Ester: <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  0.97 (t,  $J$  = 7.4 Hz, 3H), 1.42 (t,  $J$  = 7.0 Hz, 3H), 1.67 (sextuplet,  $J$  = 7.4 Hz, 2H), 2.40 (t,  $J$  = 7.4 Hz, 2H), 3.23 (d,  $J$  = 12.8 Hz, 1H), 3.60 (dd,  $J$  = 12.8, 5.3 Hz, 1H), 4.46 (dd,  $J$  = 12.6, 2.5 Hz, 1H), 4.52 (quartet,  $J$  = 7.0 Hz, 2H), 4.65 (dd,  $J$  = 12.6, 4.0 Hz, 1H), 5.37 (m, 1H), 6.29 (m, 1H), 8.12 (d,  $J$  = 6 Hz, 1H).

(j) (2R,5S)-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine

A solution of the ester from step (i) (4 mg) in NH<sub>3</sub>/MeOH (2 mL) was placed in a steel bomb with a teflon liner, sealed and heated at 70°C for 18 hours. Solvent was evaporated *in vacuo* to provide the desired product (2 mg) with HPLC, <sup>1</sup>H NMR and MS properties identical to those of an authentic sample.

Example 2

Preparation of (2R,5S)-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine

(a) 2-Chloro-4-ethoxypyrimidine

To a solution of 2,4-dichloropyrimidine (Aldrich, 10.0 g, 67.12 mmol) in abs. EtOH (120 mL) at -3°C under nitrogen atmosphere was slowly added (over 2 hours) 1M NaOEt/EtOH (68 mL, 68 mmol) and the resulting mixture stirred for 1 hour. Solvent was evaporated *in vacuo* and the residue partitioned between H<sub>2</sub>O and Et<sub>2</sub>O. The aqueous phase was extracted with Et<sub>2</sub>O and the combined organic phase was washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>) and evaporated (water aspirator pump, 35°C). The resulting residue was filtered and washed with petroleum ether to provide the desired product (8.05 g, 75%) as a yellowish solid: mp 30-31°C (lit. 35°C); <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.40 (t, J = 7.2 Hz, 3H), 4.44 (quartet, J = 7.2 Hz, 2H), 6.62 (d, J = 5.7 Hz, 1H), 8.27 (d, J = 5.7 Hz, 1H); MS *m/z* 161 (M + 3, 34%), 159 (M + 1, 100%). Anal. Calcd. for C<sub>6</sub>H<sub>7</sub>ClN<sub>2</sub>O: C, 45.44; H, 4.45; N, 17.66; Cl, 22.36. Found: C, 45.32; H, 4.41; N, 17.60; Cl, 22.43.

(b) 2-(2,2-Dimethoxyethoxy)-4-ethoxypyrimidine

To a suspension of 60% NaH/mineral oil (2.55 g, 63.96 mmol) in anhydrous DMF (70 mL) at 0°C under nitrogen atmosphere was slowly added glycolaldehyde dimethyl acetal (Aldrich, 5.65 g, 53.3 mmol). The mixture was stirred at ambient temperature for 1 hour and then transferred to a solution of the product from step (a) (8.05 g, 50.76 mmol) in anhydrous DMF (70 mL) at -55°C over 15 minutes. The mixture was allowed to warm to -20°C over 2 hours and then neutralized with AcOH. Solvent was evaporated *in vacuo* and the residue partitioned between H<sub>2</sub>O and CH<sub>2</sub>Cl<sub>2</sub>. The aqueous phase was extracted with CH<sub>2</sub>Cl<sub>2</sub> and the combined organic phase was dried (Na<sub>2</sub>SO<sub>4</sub>) and evaporated *in vacuo*. The residue was flash chromatographed (EtOAc/hexanes, 1:4) to give the desired product (7.92 g, 69%) as a colourless oil: <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.37 (t, J = 7.0 Hz, 3H), 3.44 (s, 6H), 4.36-4.43 (m, 4H), 4.78 (t, J = 5.0 Hz, 1H), 6.34 (d, J = 6.0 Hz, 1H), 8.15 (d, J = 6.0 Hz, 1H); MS *m/z* 229 (M = 1, 13%), 197 (100%). Anal. Calcd. for C<sub>10</sub>H<sub>16</sub>N<sub>2</sub>O<sub>4</sub>: C, 52.62; H, 7.07; N, 12.27. Found: C, 52.45; H, 7.01; N, 12.26.

(c) 2-[(4-Ethoxy-2-pyrimidinyl)oxy]acetaldehyde

A mixture of the product from step (b) (6.0 g, 24.4 mmol) and 90% TFA/H<sub>2</sub>O (45 ml) was heated at 50°C for 2 hours. Solvent was evaporated *in vacuo* and the residue partitioned between CHCl<sub>3</sub> and saturated NaHCO<sub>3</sub>/H<sub>2</sub>O. The aqueous phase was extracted with CHCl<sub>3</sub> (x2) and the combined extracts were dried (Na<sub>2</sub>SO<sub>4</sub>), and evaporated *in vacuo* to give the desired product (4.48 g, 94%) as a colourless oil: <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.38 (t, J = 7.0 Hz, 3H), 4.37 (quartet, J = 7.0 Hz, 2H), 4.80 (s, 2H), 6.40 (d, J = 6.0 Hz, 1H), 8.15 (d, J = 6.0 Hz, 1H), 9.74 (s, 1H); MS *m/z* 183 (M + 1, 100%). Anal. Calcd. for C<sub>8</sub>H<sub>10</sub>N<sub>2</sub>O<sub>3</sub>•0.25 H<sub>2</sub>O: C, 51.47; H, 5.67; N, 15.01. Found: C, 51.38; H, 5.69; N, 14.76.

(d) 2-[(4-Ethoxy-2-pyrimidinyl)oxy]methyl]-1,3-oxathiolan-5-ol

A mixture of the product from step (c) (4.0 g, 22.0 mmol) and 1,4-dithiane-2,5-diol (Aldrich, 1.67 g, 11.0 mmol) in anhydrous toluene (80 mL) was heated at 100°C for 2 hours. The mixture was filtered and the filtrate concentrated and dried *in vacuo* to give the desired product (6.27 g, 99%) as a waxy pale yellow oil which was used in the next step without further purification (~1:1 diastereomeric ratio by <sup>1</sup>H NMR spectroscopy). Flash chromatography (EtOAc/hexanes, 2:3) gave analytically pure material as a colourless oil: <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.37 (t, J = 7.0 Hz, 3H), 3.07 (d, J = 11.0 Hz, 1H), 3.18 (d, J = 2.3 Hz, 1H), 3.26 (dm, J = 11.0 Hz, 1H), 4.38-4.58 (m, 3H), 4.85 (dd, J = 12.0, 6.0 Hz, 1H), 5.72 (dd, J = 6.0, 4.5 Hz, 1H), 5.92 (m, 1H), 6.39 (d, J = 6.0 Hz, 1H), 8.15 (d, J = 6.0 Hz, 1H); a similar set of signals appeared for the other diastereomer; MS *m/z* 197 (M - C<sub>2</sub>H<sub>5</sub>O, 41%), 133 (100%). Anal. Calcd. for C<sub>10</sub>H<sub>14</sub>N<sub>2</sub>O<sub>4</sub>S: C, 46.50; H, 5.46; N, 10.85; S, 12.41. Found: C, 46.40; H, 5.44; N, 10.79; S, 12.49.

(e) 2-[(4-Ethoxy-2-pyrimidinyl)oxy]methyl]-1,3-oxathiolan-5-yl acetate

A mixture of the product from step (d) (1.0 g, 3.9 mmol), pyridine (0.7 mL, 0.68 g, 8.65 mmol) and  $\text{Ac}_2\text{O}$  (2.0 mL, 2.26 g, 21.2 mmol) was stirred at ambient temperature for 1.5 hours. Ice-water was added and the resulting mixture stirred for 15 minutes. The mixture was extracted with EtOAc and the combined extracts washed with saturated  $\text{NaHCO}_3/\text{H}_2\text{O}$ , dried ( $\text{Na}_2\text{SO}_4$ ), evaporated and dried *in vacuo* to give the desired product (1.15 g, 99%) as an orange oil which was used in the next step without further purification (~2:1 diastereomeric ratio by  $^1\text{H}$  NMR spectroscopy).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  1.40 (t, 3H), 2.05 (s, 3H), 3.08 (d, 1H), 3.27 (dd, 1H), 4.40-4.70 (m, 4H), 5.79 (m, 1H), 6.38 (d, 1H), 6.75 (d, 1H), 8.18 (d, 1H); a similar set of signals appeared for the minor diastereomer; MS  $m/z$  241 (M - OAc, 4%), 141 (100%). Anal. Calcd. for  $\text{C}_{12}\text{H}_{16}\text{N}_2\text{O}_5\text{S}$ : C, 47.99; H, 5.37; N, 9.33; S, 10.68. Found: C, 47.88; H, 5.43; N, 9.22; S, 10.60.

(f) (2S\*,5R\*)-4-Ethoxy-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one

To a solution of the product from step (e) (0.20 g, 0.66 mmol) in anhydrous  $\text{CH}_3\text{CN}$  (12 mL) at  $0^\circ\text{C}$  under nitrogen atmosphere was slowly added stannic chloride (Aldrich, 0.12 mL, 0.27 g, 1.05 mmol). After stirring for 2 hours at  $0^\circ\text{C}$ , 1 M  $\text{NaOH}/\text{H}_2\text{O}$  (5.5 mL, 5.5 mmol) was added. After 1 hour at  $0^\circ\text{C}$ , the mixture was neutralized with AcOH. Solvent was evaporated *in vacuo* and the residue partitioned between  $\text{CHCl}_3$  and water. The aqueous phase was extracted with  $\text{CHCl}_3$  (x2) and the combined extracts were dried ( $\text{Na}_2\text{SO}_4$ ) and concentrated *in vacuo*. The residue was flash chromatographed (EtOAc/hexanes, 2:1, then EtOAc) to give the desired product (0.10 g, 60%) as a white solid: mp  $117-118^\circ\text{C}$ ;  $^1\text{H}$  NMR ( $\text{DMSO}-d_6$ ):  $\delta$  1.26 (t, J = 7.0 Hz, 3H), 3.15 (dd, J = 12.0, 3.5 Hz, 1H), 3.51 (dd, J = 12.0, 5.5 Hz, 1H), 3.71-3.84 (m, 2H), 4.26 (quartet, J = 7.0 Hz, 2H), 5.22 (t, J = 4.0 Hz, 1H), 5.40 (t, J = 6.0 Hz, 1H), 6.0 (d, J = 7.4 Hz, 1H), 6.18 (dd, J = 5.5, 3.5 Hz, 1H), 8.25 (d, J = 7.4 Hz, 1H); MS  $m/z$  259 (M+1, 4%), 141 (100%). Anal. Calcd. for  $\text{C}_{10}\text{H}_{14}\text{N}_2\text{O}_4\text{S}$ : C, 46.50; H, 5.46; N, 10.85; S, 12.41. Found: C, 46.58; H, 5.49; N, 10.84; S, 12.34.

(g) (2S\*,5R\*)-4-Ethoxy-1-[2-(propionyloxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one

To a solution of the product from step (f) (0.30 g, 1.16 mmol) in pyridine (0.19 mL, 0.18 g, 2.32 mmol) was added butyric anhydride (0.37 mL, 0.36 g, 2.32 mmol) and the resulting mixture was stirred at ambient temperature for 2 hours. Saturated NaHCO<sub>3</sub>/H<sub>2</sub>O was added and, after 1 hour, the mixture was extracted with EtOAc (x2) and the combined extracts were dried (Na<sub>2</sub>SO<sub>4</sub>), concentrated *in vacuo* and flash chromatographed (EtOAc/hexanes, 1:1) to give the desired product (0.21 g, 55%) as a yellowish solid: mp 59-61°C; <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 0.96 (t, J = 7.4 Hz, 3H), 1.36 (t, J = 7.1 Hz, 3H), 1.68 (sextuplet, J = 7.4 Hz, 2H), 1.80 (br s, 1H), 2.36 (t, J = 7.4 Hz, 2H), 3.14 (dd, J = 12.3, 3.5 Hz, 1H), 3.59 (dd, J = 12.3, 5.2 Hz, 1H), 4.40 (m, 3H), 4.59 (dd, J = 12.3, 5.2 Hz, 1H), 5.36 (dd, J = 5.2, 3.4 Hz, 1H), 5.89 (d, J = 7.3 Hz, 1H), 6.34 (dd, J = 5.2, 3.9 Hz, 1H), 7.91 (d, J = 7.3 Hz, 1H); MS *m/z* 329 (M = 1, 11%), 141 (100%). Anal. Calcd. for C<sub>14</sub>H<sub>20</sub>N<sub>2</sub>O<sub>5</sub>S: C, 51.21; H, 6.14; N, 8.53; S, 9.76. Found: C, 51.08; H, 6.15; N, 8.39; S, 9.69.

(h) (2R,5S)-4-Ethoxy-1-[2-propionyloxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one

To a solution of the product from step (g) (10 mg) in 20% CH<sub>3</sub>CN/buffer (3.0 mL, 0.05 M, pH 8.0, phosphate) is added PLE (pig liver esterase, 1.5 µL, Sigma) and the mixture is stirred at ambient temperature for 24 hours. The aqueous solution is extracted with hexane (x2) and the combined extracts were dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated *in vacuo* to give the desired product. HPLC analysis of the organic phase indicates the presence of a single enantiomeric butyrate ester: The enantiomeric alcohol is detected in the aqueous phase.

(i) (2R,5S)-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine

A solution of the ester from step (h) (4 mg) in  $\text{NH}_3/\text{MeOH}$  (2 mL) is placed in a steel bomb with a teflon liner, sealed and heated at  $70^\circ\text{C}$  for 18 hours. Solvent is evaporated *in vacuo* to give the desired product with HPLC,  $^1\text{H}$  NMR and MS properties identical to those of an authentic sample.

Example 3

(2S\*,5R\*)-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine

A solution of the product from step (g) (10 mg) in  $\text{NH}_3/\text{MeOH}$  (2 mL of MeOH saturated with  $\text{NH}_3$  gas at  $0^\circ\text{C}$  for 45 minutes) was placed in a steel bomb with a teflon liner, sealed and heated at  $70^\circ\text{C}$  for 18 hours. Solvent was evaporated *in vacuo* and acetone added to give the desired product (8.8 mg, 99%) as a white solid: mp  $195\text{--}196^\circ\text{C}$ ;  $^1\text{H}$  NMR ( $\text{DMSO}-d_6$ ):  $\delta$  3.10 (dd,  $J = 12.0, 4.2$  Hz, 1H), 3.40 (dd,  $J = 12.0, 5.3$  Hz, 1H), 3.70 (ddd,  $J = 12.0, 5.5, 3.5$  Hz, 1H), 3.77 (ddd,  $J = 12.0, 5.5, 3.5$  Hz, 1H), 5.16 (t,  $J = 3.5$  Hz, 1H), 5.39 (t,  $J = 5.5$  Hz, 1H), 6.11 (m, 1H), 7.56 (br s, 1H), 7.80 (br s, 1H), 8.17 (d,  $J = 7.4$  Hz, 1H); MS  $m/z$  248 ( $M + 1$ , 34%), 130 (100%). Anal. Calcd. for  $\text{C}_8\text{H}_{10}\text{FN}_3\text{O}_3\text{S}$ : C, 38.86; H, 4.08; N, 17.00; S, 12.97. Found: C, 38.97; H, 4.05; N, 16.96; S, 12.95.

Example 4


(2S\*,5R\*)-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine

A solution of (2S\*, 5R\*)-4-ethoxy-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one (0.21g) in ammonia/methanol (8 mL of methanol saturated with ammonia gas at  $0^\circ\text{C}$  for 45 minutes) was placed in a steel bomb with a teflon liner, sealed and heated at  $70^\circ\text{C}$  for 18 hours. Solvent was evaporated *in vacuo* and the residue subjected to flash chromatography to give the desired product (0.16g, 89%) as a white solid: mp  $184\text{--}185^\circ\text{C}$ ;  $^1\text{H}$  NMR ( $\text{DMSO}-d_6$ ):  $\delta$  3.00 (dd,  $J = 11.8, 5.0$  Hz, 1H), 3.38 (dd,  $J = 11.8, 5.5$  Hz, 1H),

3.63-3.80 (m, 2H), 5.15 (t,  $J = 4.5$  Hz, 1H), 5.30 (t,  $J=6.0$  Hz, 1H), 5.70 (d,  $J = 7.3$  Hz, 1H); 6.18 (t,  $J=5.0$  Hz, 1H), 7.20 (brd, 2H,  $\text{NH}_2$ ), 7.79 (d,  $J=7.3$  Hz, 1H); MS  $m/z$  229.8 ( $M + 1$ , 4%), 112 (100%). Anal. Calcd. for  $\text{C}_8\text{H}_{11}\text{N}_3\text{O}_3\text{S}$ : C, 41.91; H, 4.84; N, 18.33; S, 13.99. Found: C, 41.97; H, 4.83; N, 18.24; S, 13.93


**CLAIMS**

1. A process for the preparation of compounds of formula (I)



wherein R is hydrogen, C<sub>1-6</sub> alkyl, or halogen and Y is hydroxy, amino, C<sub>1-6</sub> alkoxy or OR<sup>1</sup>, where R<sup>1</sup> is a chiral auxiliary;


which process comprises treating a compound of formula (II)



wherein R and Y are as hereinbefore defined and R<sup>2</sup> represents hydrogen, C<sub>1-6</sub>acyl, C<sub>1-6</sub>alkyl or halogen with a suitable Lewis acid or a reagent apt to convert the group OR<sup>2</sup> to a leaving group.


2. A process for the preparation of a compound of formula (Ia)





(Ia)


wherein R is hydrogen, C<sub>1-6</sub>alkyl, or halogen, and Y is hydroxy, amino, C<sub>1-6</sub> alkoxy or OR<sup>1</sup>, where R<sup>1</sup> is a chiral auxiliary, which process comprises treating a compound of formula (IIa)



(IIa)


wherein R, Y and R<sup>2</sup> are as previously defined with a suitable Lewis acid or a reagent apt to convert the group OR<sup>2</sup> to a leaving group.

3. A process according to Claim 1 or Claim 2 wherein the Lewis acid is stannic chloride or trimethylsilyl triflate.
4. A process according to Claim 3 wherein the Lewis acid is stannic chloride and the treatment is carried out at reduced temperature in a polar aprotic solvent.
5. A process according to any of Claims 1 to 4 wherein the compound of formula (II) is prepared by reacting a compound of formula (III)



wherein R is hydrogen, C<sub>1-6</sub> alkyl, or halogen, and Y is hydroxy, amino, C<sub>1-6</sub> alkoxy, or OR<sup>1</sup> where R<sup>1</sup> is a chiral auxiliary, with 1,4-dithiane-2,5-diol and, if necessary or desired, derivatisation.


6. A process according to Claim 5 wherein the reaction with 1,4-dithiane-2,5-diol is carried out at elevated temperature in a non-polar aprotic solvent.
7. A process according to Claim 6 wherein the reaction with 1,4-dithiane-2,5-diol is carried out at about 100°C in anhydrous toluene.
8. A method for obtaining a compound of formula (IIa) wherein R is H and Y is OR<sup>1</sup> from a mixture of isomers by treatment of the mixture of isomers, at least partially in solution, with an agent capable of effecting interconversion of the isomers without complete suppression of the crystallisation of the desired single enantiomer (IIa) wherein R is H and Y is OR<sup>1</sup>.
9. A compound of formula (IV)



wherein R (which may be the same or different) is hydrogen, C<sub>1-6</sub> alkyl, or halogen, and Y is hydroxy, amino, C<sub>1-6</sub> alkoxy, or OR<sup>1</sup> where R<sup>1</sup> is a chiral auxiliary, which compound is selected from 2-(2,2-


dimethoxyethoxy)-4-ethoxy-5-fluoropyrimidine and 2-(2,2-dimethoxyethoxy)-4-ethoxy-5-pyrimidine.

10. A compound of formula (III)




as defined in Claim 5, which compound is selected from 2-[(4-ethoxy-5-fluoro-2-pyrimidinyl)oxy]acetaldehyde and 2-[(4-ethoxy-2-pyrimidinyl)oxy]acetaldehyde.

11. A compound of formula (II)




as defined in Claim 1, which compound is selected from 2-[[[(4-ethoxy-5-fluoro-2-pyrimidinyl)oxy]methyl]-1,3-oxathiolan-5-yl] and 2-[[[(4-ethoxy-2-pyrimidinyl)-oxy]methyl]-1,3-oxathiolan-5-yl], 2-[[[(4-ethoxy-5-fluoro-2-pyrimidinyl)oxy]methyl]-1,3-oxathiolan-5-yl] acetate and 2-[[[(4-ethoxy-2-pyrimidinyl)oxy]methyl]-1,3-oxathiolan-5-yl] acetate.

12. A compound of formula (IIa)




wherein R represents hydrogen, C<sub>1-6</sub>alkyl or halogen, R<sup>2</sup> represents hydrogen, C<sub>1-6</sub>acyl, C<sub>1-6</sub>alkyl or halogen and Y represents OR<sup>1</sup> wherein R<sup>1</sup> represents (d)-menthyl, (l)-menthyl, (d)-8-phenylmenthyl, (l)-8-phenylmenthyl, (+)-norephedrine or (-)-norephedrine.

13. A compound as claimed in Claim 12 wherein R<sup>1</sup> represents (l)-menthyl.
14. A compound of formula (I)




as defined in Claim 1, which compound is selected from (2S\*, 5R\*)-4-ethoxy-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one and (2S\*, 5R\*)-4-ethoxy-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one.

15. A compound of formula (VIII)




wherein R (which may be the same or different) is hydrogen, C<sub>1-6</sub> alkyl, or halogen, X is S, and Y is hydroxy, amino, or C<sub>1-6</sub> alkoxy, which compound is selected from (2S\*, 5R\*)-4-ethoxy-5-fluoro-1-[2-propionyloxymethyl]-1,3-oxathiolan-5-yl]pyrimidin-2-one and (2S\*, 5R\*)-4-ethoxy-1-[2-(propionyloxy-methyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one.

16. A compound of formula (IX)



wherein R is hydrogen, C<sub>1-6</sub> alkyl, or halogen and Y is hydroxy, amino, or C<sub>1-6</sub> alkoxy, which compound is selected from (2S, 5R)-4-ethoxy-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one and (2S, 5R)-4-ethoxy-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one.

17. A compound of formula (X)



wherein R (which may be the same or different) is hydrogen, C<sub>1-6</sub> alkyl, or halogen and Y is hydroxy, amino, or C<sub>1-6</sub> alkoxy, which compound is selected from (2R, 5S)-4-ethoxy-5-fluoro-1-[2-(propionyloxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one and (2R, 5S)-4-ethoxy-1-[2-(propionyloxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one.

## INTERNATIONAL SEARCH REPORT

Int. Patent Application No.

PCT/EP 96/01353

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D411/04 C07D239/00 //C07H19/06

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D C07H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	JP,A,06 263 792 (NOGUCHI KENKYUSHO) 20 September 1994 cited in the application see the whole document	1-17
Y	WO,A,91 11186 (EMORY UNIVERSITY) 8 August 1991 cited in the application see abstract	1-17



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

- \* 'A' document defining the general state of the art which is not considered to be of particular relevance
- \* 'E' earlier document but published on or after the international filing date
- \* 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \* 'O' document referring to an oral disclosure, use, exhibition or other means
- \* 'P' document published prior to the international filing date but later than the priority date claimed

\* 'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\* 'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\* 'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\* 'A' document member of the same patent family

Date of the actual completion of the international search

27 August 1996

Date of mailing of the international search report

04-09-1996

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tlx. 31 651 epo nl,  
Fax (+ 31-70) 340-3016

Authorized officer

Scott, J

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 96/01353

## C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	JOURNAL OF ORGANIC CHEMISTRY, vol. 57, no. 21, 1992, EASTON US, pages 5563-5565, XP002007516 L.K.HOONG ET AL.: "Enzyme-mediated Enantioselective Preparation of Pure Enantiomers of Antiviral Agent 2',3'-dideoxy-5-fluoro-3'-thiacytidine (FTC) and Related Compounds." see the whole document ---	1-17
Y	US,A,5 210 085 (LIOTTA ET AL.) 11 May 1993 see the whole document ---	1-17
Y	WO,A,92 20669 (BIOCHEM. PHARMA INC.) 26 November 1992 cited in the application see the whole document ---	1-17
Y	JOURNAL OF MEDICINAL CHEMISTRY, vol. 36, no. 2, 1993, WASHINGTON US, pages 181-195, XP002007517 L.S.JEONG ET AL.: "Asymmetric Synthesis and Biological Evaluation of beta-L-(2R,5S)- and alpha-L-(2R,5R)-1,3-oxathiolane-pyrimidine and -purine Nucleosides as Potential anti-HIV Agents." see the whole document ---	1-17
Y	JOURNAL OF MEDICINAL CHEMISTRY, vol. 36, no. 18, 1993, WASHINGTON US, pages 2627-2638, XP002007518 L.S.JEONG ET AL.: "Structure-Activity Relationships of beta-D-(2S,5R)- and alpha-D-(2S,5S)-1,3-oxathiolanyl Nucleosides as Potential Anti-HIV Agents." see the whole document ---	1-17
P,X	WO,A,95 29174 (GLAXO GROUP LTD.) 2 November 1995 cited in the application see the whole document -----	14,16



## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 96/01353

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
JP-A-6263792	20-09-94	NONE	
WO-A-9111186	08-08-91	US-A- 5204466	20-04-93
		AU-B- 4031995	26-04-96
		AU-B- 658136	06-04-95
		AU-B- 7300491	21-08-91
		CA-A- 2075189	02-08-91
		DE-T- 513200	13-07-95
		EP-A- 0513200	19-11-92
		ES-T- 2076130	01-11-95
		JP-B- 7000618	11-01-95
		US-A- 5539116	23-07-96
		US-A- 5210085	11-05-93
		US-A- 5276151	04-01-94
US-A-5210085	11-05-93	US-A- 5204466	20-04-93
		AU-B- 1437292	15-09-92
		AU-B- 665187	21-12-95
		AU-B- 1561792	15-09-92
		AU-B- 3794395	14-03-96
		BG-A- 98062	25-04-94
		BR-A- 9205661	24-05-94
		CA-A- 2104399	23-08-92
		CN-A- 1065065	07-10-92
		EP-A- 0575482	29-12-93
		HU-A- 65548	28-06-94
		JP-T- 6508605	29-09-94
		NZ-A- 241625	26-03-96
		NZ-A- 250842	26-03-96
		WO-A- 9214743	03-09-92
		WO-A- 9214729	03-09-92
		US-A- 5276151	04-01-94
		ZA-A- 9201251	20-08-93
		AU-B- 4031995	26-04-96
		AU-B- 658136	06-04-95
		AU-B- 7300491	21-08-91
		CA-A- 2075189	02-08-91
		DE-T- 513200	13-07-95
		EP-A- 0513200	19-11-92
		ES-T- 2076130	01-11-95

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 96/01353

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-5210085		JP-B- 7000618	11-01-95
		US-A- 5539116	23-07-96
		WO-A- 9111186	08-08-91
<hr/>			
WO-A-9220669	26-11-92	AT-T- 133958	15-02-96
		AU-B- 655973	19-01-95
		AU-B- 1639492	26-11-92
		AU-B- 668086	26-04-96
		AU-B- 1639592	26-11-92
		AU-B- 1690892	30-12-92
		AU-B- 1691392	30-12-92
		BG-A- 98310	03-01-95
		BG-A- 98311	15-08-94
		CA-A- 2069024	22-11-92
		CA-A- 2069063	22-11-92
		WO-A- 9220696	26-11-92
		CN-A- 1067654	06-01-93
		CN-A- 1067245	23-12-92
		CN-A- 1116204	07-02-96
		CZ-A- 9302492	16-03-94
		CZ-A- 9302493	13-04-94
		DE-D- 69208144	21-03-96
		EP-A- 0515156	25-11-92
		EP-A- 0515157	25-11-92
		ES-T- 2084937	16-05-96
		FI-A- 960286	19-01-96
		HU-A- 67726	28-04-95
		HU-A- 67471	28-04-95
		JP-A- 5186465	27-07-93
		JP-A- 5186463	27-07-93
		NZ-A- 242817	28-03-95
		NZ-A- 242818	27-04-94
		PL-B- 168910	31-05-96
		SK-A- 129393	06-07-94
		SK-A- 129493	09-11-94
<hr/>			
WO-A-9529174	02-11-95	AU-B- 2447195	16-11-95
<hr/>			